









市場行情
/
股票
/
nasdaq-ions
/

Ionis Pharmaceuticals Inc

IONS

80.300USD

-1.240-1.52%

收盤 01/09, 16:00（美東）報價延遲15分鐘

12.94B總市值

虧損本益比TTM



Ionis Pharmaceuticals Inc

80.300

-1.240-1.52%

概覽公司財務分析

概覽

公司

財務

分析

關於 Ionis Pharmaceuticals Inc 公司

Ionis Pharmaceuticals, Inc. develops six marketed medicines for serious diseases, including medicines for neurologic and cardiovascular diseases. Its marketed medicines consist of TRYNGOLZA, WAINUA (eplontersen), SPINRAZA (nusinersen), QALSODY (tofersen), TEGSEDI (inotersen) and WAYLIVRA (volanesorsen). TRYNGOLZA reduces triglyceride levels in adults with familial chylomicronemia syndrome (FCS). WAINUA is approved for the treatment of the polyneuropathy of hereditary transthyretin-medicated amyloidosis (ATTRv-PN) in adults. SPINRAZA is used for the treatment of pediatric and adult patients with spinal muscular atrophy. QALSODY is approved for the treatment of Amyotrophic Lateral Sclerosis in adults who have a mutation in the superoxide dismutase 1 (SOD1) gene, or SOD1-ALS. TEGSEDI is approved for the treatment of ATTRv-PN in adults. WAYLIVRA is approved as an adjunct to diet in adult patients with genetically confirmed FCS and at high risk of acute, potentially fatal pancreatitis.

Ionis Pharmaceuticals Inc簡介



公司代碼IONS

公司名稱Ionis Pharmaceuticals Inc

上市日期May 17, 1991

CEOMonia (Brett P)

員工數量1069

證券類型Ordinary Share

年結日May 17

公司地址2855 Gazelle Court

城市CARLSBAD

上市交易所NASDAQ OMX - NASDAQ BASIC

國家United States of America

郵編92010

電話17609319200

網址https://www.ionis.com/

公司代碼IONS

上市日期May 17, 1991

CEOMonia (Brett P)

Ionis Pharmaceuticals Inc公司高管



名稱

名稱/職務

職務

持股

持股變動

Dr. Brett P. Monia, Ph.D.

Chief Executive Officer, Director

179.57K

-437.00%

Dr. Spencer R. Berthelsen, M.D.

Independent Director

156.08K

+4079.00%

Ms. Elizabeth L. Hougen

Chief Financial Officer, Executive Vice President - Finance

110.50K

Dr. Richard S. Geary, Ph.D.

Executive Vice President, Chief Development Officer

59.66K

Mr. Patrick R. O'Neil, Esq.

Executive Vice President, Chief Legal Officer, General Counsel and Corporate Secretary

53.89K

-3241.00%

Mr. Brian Birchler

Executive Vice President, Chief Business Officer

48.83K

-8000.00%

Mr. Eugene Schneider, M.D.

Executive Vice President, Chief Clinical Development and Operations Officer

47.47K

Dr. Joseph Loscalzo, M.D., Ph.D.

Independent Chairman of the Board

36.33K

Dr. Eric E. Swayze, Ph.D.

Executive Vice President - Research

30.57K

Ms. Shannon L. Devers

Chief Human Resources Officer, Executive Vice President

17.49K

名稱

名稱/職務

職務

持股

持股變動

Dr. Brett P. Monia, Ph.D.

Chief Executive Officer, Director

179.57K

-437.00%

Dr. Spencer R. Berthelsen, M.D.

Independent Director

156.08K

+4079.00%

Ms. Elizabeth L. Hougen

Chief Financial Officer, Executive Vice President - Finance

110.50K

Dr. Richard S. Geary, Ph.D.

Executive Vice President, Chief Development Officer

59.66K

Mr. Patrick R. O'Neil, Esq.

Executive Vice President, Chief Legal Officer, General Counsel and Corporate Secretary

53.89K

-3241.00%

Mr. Brian Birchler

Executive Vice President, Chief Business Officer

48.83K

-8000.00%

收入明細

單位: USD更新時間: 3月4日週二

FY2020

FY2019

業務USD

名稱

營收

佔比

R&D revenue under collaborative agreements

364.56M

49.99%

SPINRAZA royalties

286.58M

39.30%

Product sales, net

70.00M

9.60%

Licensing and other Royalty revenue

8.12M

1.11%

由於公司未披露，未能獲取相關數據

業務

地區

業務USD

名稱

營收

佔比

R&D revenue under collaborative agreements

364.56M

49.99%

SPINRAZA royalties

286.58M

39.30%

Product sales, net

70.00M

9.60%

Licensing and other Royalty revenue

8.12M

1.11%

股東統計

更新時間: 11月19日週三

持股股東

股東類型

持股股東

佔比

Fidelity Management & Research Company LLC

14.63%

Capital World Investors

11.09%

The Vanguard Group, Inc.

10.15%

T. Rowe Price Investment Management, Inc.

8.12%

BlackRock Institutional Trust Company, N.A.

5.22%

其他

50.79%

持股股東

佔比

Fidelity Management & Research Company LLC

14.63%

Capital World Investors

11.09%

The Vanguard Group, Inc.

10.15%

T. Rowe Price Investment Management, Inc.

8.12%

BlackRock Institutional Trust Company, N.A.

5.22%

其他

50.79%

股東類型

持股股東

佔比

Investment Advisor

68.58%

Investment Advisor/Hedge Fund

19.53%

Hedge Fund

13.84%

Research Firm

2.62%

Pension Fund

1.04%

Bank and Trust

0.81%

Individual Investor

0.75%

Sovereign Wealth Fund

0.28%

Family Office

0.02%

機構持股



更新時間: 1月1日週四

報告期間

機構數

持股數

持股佔比

持股變動

2025Q4

841

178.22M

110.03%

-6.52M

2025Q3

815

172.95M

106.78%

-7.24M

2025Q2

801

185.40M

116.34%

+8.33M

2025Q1

826

174.18M

109.45%

-1.97M

2024Q4

819

166.51M

104.84%

-2.69M

2024Q3

814

162.85M

103.55%

+6.60M

2024Q2

810

149.96M

102.64%

-3.87M

2024Q1

792

148.14M

101.63%

-5.27M

2023Q4

782

147.15M

102.53%

-3.26M

2023Q3

763

145.13M

101.24%

-1.40M

股東持股明細



名稱

持股數

佔比

持股變動

變動比例

公告日期

Fidelity Management & Research Company LLC

23.69M

14.63%

+46.05K

+0.19%

Sep 30, 2025

Capital World Investors

17.96M

11.09%

+5.24M

+41.17%

Dec 31, 2025

The Vanguard Group, Inc.

16.44M

10.15%

-235.68K

-1.41%

Sep 30, 2025

T. Rowe Price Investment Management, Inc.

13.16M

8.12%

-2.89M

-18.02%

Sep 30, 2025

BlackRock Institutional Trust Company, N.A.

8.45M

5.22%

-272.23K

-3.12%

Sep 30, 2025

Wellington Management Company, LLP

6.59M

4.07%

+243.03K

+3.83%

Sep 30, 2025

Bellevue Asset Management AG

6.24M

3.86%

-1.61M

-20.49%

Sep 30, 2025

State Street Investment Management (US)

4.39M

2.71%

-141.75K

-3.13%

Sep 30, 2025

Deep Track Capital LP

3.81M

2.35%

-1.08M

-22.15%

Sep 30, 2025

Two Sigma Investments, LP

3.65M

2.25%

-806.92K

-18.11%

Sep 30, 2025

持股ETF



更新時間: 12月6日週六

機構名稱

佔比

Invesco Biotechnology & Genome ETF

5.24%

ARK Genomic Revolution ETF

4.11%

Virtus LifeSci Biotech Products ETF

3.34%

Franklin Genomic Advancements ETF

2.69%

Invesco Dorsey Wright Healthcare Momentum ETF

2.57%

First Trust Health Care Alphadex Fund

2.47%

VanEck Morningstar SMID Moat ETF

2.38%

WisdomTree BioRevolution Fund

2.28%

State Street SPDR S&P Biotech ETF

2.28%

Capital Group US Small and Mid Cap ETF

2.04%

Invesco Biotechnology & Genome ETF

佔比5.24%

ARK Genomic Revolution ETF

佔比4.11%

Virtus LifeSci Biotech Products ETF

佔比3.34%

Franklin Genomic Advancements ETF

佔比2.69%

Invesco Dorsey Wright Healthcare Momentum ETF

佔比2.57%

First Trust Health Care Alphadex Fund

佔比2.47%

VanEck Morningstar SMID Moat ETF

佔比2.38%

WisdomTree BioRevolution Fund

佔比2.28%

State Street SPDR S&P Biotech ETF

佔比2.28%

Capital Group US Small and Mid Cap ETF

佔比2.04%

分紅派息



近5年累計派現 0.00 美元

公告日期

分紅計劃

股權登記日

現金發放日

除權除息日

暫無數據

拆合股



公告日期

類型

比率

暫無數據

公告日期

類型

比率

暫無數據

常見問題

Ionis Pharmaceuticals Inc的前五大股東是誰？



Ionis Pharmaceuticals Inc的前五大股東如下：
Fidelity Management & Research Company LLC
持有股份：23.69M
佔總股份比例：14.63%。
Capital World Investors
持有股份：17.96M
佔總股份比例：11.09%。
The Vanguard Group, Inc.
持有股份：16.44M
佔總股份比例：10.15%。
T. Rowe Price Investment Management, Inc.
持有股份：13.16M
佔總股份比例：8.12%。
BlackRock Institutional Trust Company, N.A.
持有股份：8.45M
佔總股份比例：5.22%。